Background Image
Previous Page  157 / 182 Next Page
Information
Show Menu
Previous Page 157 / 182 Next Page
Page Background

156

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

42

ChungS, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children

during catheterization for voiding cystourethrography. Pediatr Radiol 2010; 40(7): 1236-

1240.

43

Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakt-

hrough pain. Seminars in Oncology 1997; 24 (Suppl. 16): 13-19.

44

Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Annals

of teh Academy of Medicine 1994; 23: 129-138.

45

Colberg T, Nolte T, Oronska A, Kaczmarek Z, Kaasa S, Kress H. Titration of intranasal fen-

tanyl for breakthrough pain in patients with cancer: evidence for dose proportionality

vs. background analgesia. Ann Oncol 2009; 19 (Suppl. 8): 257-258.

46

Cole J, Shepherd M, Young P. Intranasal fentanyl in 1–3-year-olds: a prospective study of

the effectiveness of intranasal fentanyl as acute analgesia. Emerg Med Australas 2009;

21(5): 395-400.

47

Colleau SM. The significance of breakthrough pain in cancer. Cancer Pain Release 1999;

12(4): 1-4.

48

Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley

J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial

comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate

release (MSIR). Pain 2001; 91: 123-30.

49

CrellinD, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 μg/

ml) administered intranasally have analgesic efficacy? Emerg Med Australas 201: 22(1):

62-67.

50

Dahl JL. How to reduce fears of legal/regulator scrutin in managing pain in cancer pati-

ents. Journal of Supportive Oncology 2005; 3: 384-388.

51

Dahm P, Lundborg C, Janson M, Olegard C, Nitescu P. Comparison of 0.5% intrathecal

bupivacaine with 0.5% intrathecal ropivacaine in the treatment of refractory cancer and

noncancer pain conditions: results from a prospective, crossover, double-blind, rando-

mized study. Regional Anesthesia and Pain Medicine 2000; 25: 480-487.

52

Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P. Bioequivalence following buc-

cal tablet 400 microg in healthy subjects. Clin Drug Invest 2008; 28: 1-7.

53

Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Pharmacokinetic properties

of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-

dose 100, 200, 400, and 800 mg in healthy adult volunteers. Clin Ther 2006; 28(5):

707-714.

54

Darwish M, Kirby M, Robertson P Jr, Tracewell W, Xie F. Dose proportionality of fentanyl

buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a

randomized, open-label, four-period, crossover, single-centre study. Clin Drug Investig

2010; 30(6): 365-373.

55

Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and relative bioavaila-

bility of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol

2007; 47: 343-350.

Literaturverzeichnis